{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:06Z","timestamp":1753891926936,"version":"3.41.2"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>TRC150094, a novel mitochondrial modulator, can restore metabolic flexibility by improving insulin resistance in preclinical studies. This study primarily aims to evaluate the safety, tolerability, and pharmacokinetics (PK) of oral TRC150094 after conducting two double-blind, randomized, Phase-I studies, single ascending dose (SAD) and multiple ascending dose (MAD), with <jats:italic>n<\/jats:italic> = 46, in overweight\/obese adult and elderly subjects. In addition, the effect of TRC150094 on pharmacodynamic (PD) efficacy markers was evaluated. PK assessments, including maximum concentration (C<jats:sub>max<\/jats:sub>), area under the plasma concentration (AUC), time to C<jats:sub>max<\/jats:sub> (T<jats:sub>max<\/jats:sub>), and elimination half-life (t\u00bd), were assessed at pre-specified time points. PD assessments included apolipoprotein B (ApoB), triglycerides, hepatic fat by magnetic resonance spectroscopy (MRS) and cardiopulmonary exercise testing (CPET) parameters. TRC150094 was rapidly absorbed, and the AUC of TRC150094 increased in a dose-dependent manner across all doses in non-elderly and elderly cohorts. C<jats:sub>max<\/jats:sub> was more than the dose-proportional for all doses in all cohorts. T<jats:sub>max<\/jats:sub> ranged from 0.25 to 4\u00a0h, and t\u00bd ranged from 15 to 18\u00a0h, making TRC150094 suitable for once-daily dosing. Food did not interfere with the overall absorption of the drug. The metabolites of TRC150094 were glucuronide and sulfate conjugates, and 20% of the drug was excreted unchanged in the urine. TRC150094 at 50\u00a0mg showed an improving trend in triglycerides. A significant reduction in Apo B was observed after 50\u00a0mg dose (\u22122.34 vs. 13.24%, <jats:italic>p<\/jats:italic> = 0.008), which was, however, not the case after 150\u00a0mg (8.78 vs. 13.24%, <jats:italic>p<\/jats:italic> = 0.1221). Other parameters such as hepatic fat and insulin sensitivity indices (HOMA-IR, MATSUDA Index derived from OGTT) showed an improving trend for the dose of 50\u00a0mg. In terms of safety, all the AEs reported were mild to moderate in severity. None of the adverse events was considered definitely or probably related to treatment, and there were no abnormal laboratory findings. In conclusion, the PK of TRC150094 was linear with no clinically significant food effect. TRC150094 and its metabolites suggest a lesser likelihood of drug-drug interactions. Overall, TRC150094 ensured safety and exhibited suitability for all subjects.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold> EUDRA CT: <jats:ext-link>2009-014941-10 (SAD)<\/jats:ext-link> and CTR-India registration: <jats:ext-link>CTRI\/2009\/091\/000601<\/jats:ext-link> (MAD)<\/jats:p>","DOI":"10.3389\/fphar.2021.729424","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T15:33:56Z","timestamp":1631892836000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety, Tolerability, and Pharmacokinetics of a Novel Mitochondrial Modulator, TRC150094, in Overweight and Obese Subjects: A Randomized Phase-I Clinical Trial"],"prefix":"10.3389","volume":"12","author":[{"given":"Deepa","family":"Joshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Jamadarkhana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suchit","family":"Kumbhare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jignesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Bunger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Shiwalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anookh","family":"Mohanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitanya","family":"Dutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of Systolic Blood Pressure with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 36): Prospective Observational Study","volume":"321","author":"Adler","year":"2000","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1089\/ars.2009.2788","article-title":"Potential Therapeutic Benefits of Strategies Directed to Mitochondria","volume":"13","author":"Camara","year":"2010","journal-title":"Antioxid. Redox Signal"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1096\/fj.10-157115","article-title":"TRC150094, a Novel Functional Analog of Iodothyronines, Reduces Adiposity by Increasing Energy Expenditure and Fatty Acid Oxidation in Rats Receiving a High\u2010fat Diet","volume":"24","author":"Cioffi","year":"2010","journal-title":"FASEB j."},{"key":"B4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12944-020-01292-w","article-title":"Apolipoprotein B and Non-high-density Lipoprotein Cholesterol Reveal a High Atherogenicity in Individuals with Type 2 Diabetes and Controlled Low-Density Lipoprotein-Cholesterol","volume":"19","author":"Fonseca","year":"2020","journal-title":"Lipids Health Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s10541-005-0097-0","article-title":"Biological Effects of 3,5-diiodothyronine (T2)","volume":"70","author":"Goglia","year":"2005","journal-title":"Biochemistry (Moscow)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/009286159502900324","article-title":"Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry\/Pharmacokinetics UK Joint Working Party","volume":"29","author":"Gough","year":"1995","journal-title":"Drug Inf. J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1161\/CIR.000000000000062510.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2147\/DMSO.S286888","article-title":"Metabolic and Energy Imbalance in Dysglycemia-Based Chronic Disease","author":"Kalra","year":"2021","journal-title":"Dmso"},{"key":"B9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jacc.2019.11.044","article-title":"Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-Of-The-Art Review","volume":"75","author":"Mechanick","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B10","first-page":"107843","article-title":"Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas","volume-title":"Diabetes Research and Clinical Practice","author":"Saeedi","year":"2019"},{"key":"B11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fphys.2019.00532","article-title":"Mitochondrial (Dys)Function and Insulin Resistance: From Pathophysiological Molecular Mechanisms to the Impact of Diet","volume":"10","author":"Sergi","year":"2019","journal-title":"Front. Physiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1039\/c2mb25055a","article-title":"Metabolic Effects of the Iodothyronine Functional Analogue TRC150094 on the Liver and Skeletal Muscle of High-Fat Diet Fed Overweight Rats: An Integrated Proteomic Study","volume":"8","author":"Silvestri","year":"2012","journal-title":"Mol. Biosyst."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","article-title":"Diabetes, Hypertension, and Cardiovascular Disease: an Update","volume":"37","author":"Sowers","year":"2001","journal-title":"Hypertension"},{"key":"B14","doi-asserted-by":"publisher","first-page":"H1597","DOI":"10.1152\/ajpheart.00026.2004","article-title":"Insulin Resistance and Hypertension","volume":"286","author":"Sowers","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiolheart Circulatory Physiol."},{"volume-title":"Bioanalytical Method Validation Guidance for Industry","year":"2018","key":"B15"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e86890","DOI":"10.1371\/journal.pone.0086890","article-title":"The Effect of a Diiodothyronine Mimetic on Insulin Sensitivity in Male Cardiometabolic Patients: A Double-Blind Randomized Controlled Trial","volume":"9","author":"van der Valk","year":"2014","journal-title":"PLoS ONE"},{"key":"B17","unstructured":"WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Subjects \u2013 WMA \u2013 the World Medical Association"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/DMSOTT.S15323","article-title":"TRC150094 Attenuates Progression of Nontraditional Cardiovascular Risk Factors Associated with Obesity and Type 2 Diabetes in Obese ZSF1 Rats","volume":"4","author":"Zambad","year":"2011","journal-title":"Diabetes Metab. Syndr. Obes."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.729424\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T15:34:03Z","timestamp":1631892843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.729424\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":18,"alternative-id":["10.3389\/fphar.2021.729424"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.729424","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"article-number":"729424"}}